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INTRODUCTION
Statins are widely used compounds in hypercholesterolemic
patients reducing the risk of cardiovascular (CV) events. As
a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
tors (statins) are extremely effective at reducing low-density
lipoprotein (LDL) cholesterol and have been demonstrated
to reduce mortality and the risk of coronary heart disease
(CHD) in a number of large primary and secondary preven-
tion studies [1]. In recent years, however, a number of addi-
tional non-lipid-lowering, or «pleiotropic», effects of statins
have been suggested as contributing to their efficacy in CV
disease. Statins have been shown to reduce CHD events by
as much as 37% in clinical trials, not only by lowering LDL
cholesterol levels but also by other effects in inflammation,
thrombogenesis, and arterial vasomotor function [2]. More-
over, an effect of statin on vitamin D metabolism has been
suggested as an additional mechanism of action by which
statins may exert pleiotropic effects [3].
Vitamin D receptors are present in a large variety of cell
types including myocytes, cardiomyocytes, pancreatic beta-
-cells, vascular endothelial cells, neurons, immune cells, and
osteoblast. Vitamin D has been shown to be important in
many common diseases other than the well-understood ric-
kets in children and osteomalacia and osteoporosis in adults.
Vitamin D deficiency seems to predispose to hypertension,
diabetes and the metabolic syndrome, left ventricular hyper-
trophy, congestive heart failure, and chronic vascular inflam-
mation [4]. A study of male health professionals showed a two-
-fold increased risk of myocardial infarction (MI) in subjects who
were vitamin D deficient compared to those in the sufficient
range [5]. In a different observational study, Pilz et al. [6]
found that for an approximate 20 ng/mL increase in 25-hydro-
xyvitamin D, there was a 33% decrease in the risk of a fatal
stroke. Furthermore, several studies have shown that an in-
creased exposure to sunlight protects against CHD through
production of 25(OH)D [7, 8].
It is extremely important, therefore, to establish the rela-
tion between statin and vitamin D level in CV disease pre-
vention.
VITAMIN D METABOLISM AND ACTION
Vitamin D is photosynthesised in the human epidermis as
a product of 7-dehydrocholesterol (7-DHC) irradiation with
UVB. This process produces a previtamin D, which is thermo-
converted to vitamin D3 (Fig. 1). Excessive exposure to UVB
results in degradation of vitamin D as well as previtamin D to
Figure 1. Vitamin D metabolism pathway
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inactive photoproducts. In a case of oral supplementation,
vitamin D (D3 and D2) undergoes intestinal absorption, and is
transferred with chylomicron remnants to the venal blood.
Once in the circulation, vitamin D is taken up by the liver
where it is converted to its first metabolite 25-hydroxyvita-
min D (25-OHD, preferred blood level 75–150 nmol/L),
which in turn is further hydroxylated in the kidney to form
the active, hormonal form of vitamin D — 1,25-dihydroxy-
vitamin D (1,25(OH)2D). The concentration of the hormonal
form of vitamin D is in the picomolar range and is regulated
by affecting its production and catabolism by such factors
as calcium and phosphate ions, fibroblast growth factor 23
(FGF-23), and parathormone (PTH). 1,25(OH)2D also feed-
back-downregulates its own production, at the same time do-
wnregulating PTH excretion by the parathyroid glands, and
stimulating kidney 24-hydroxylase which conducts the first
reaction of the catabolic inactivation of vitamin D [9, 10].
The so-called ‘classic’ action of vitamin D is focused on
calcium and phosphorus homeostasis of the human organism.
In response to a decrease in calcium concentration in the cir-
culation, there is an increase in PTH secretion from the para-
thyroid gland. This powerful hormone acts to quickly reple-
nish the blood calcium stores by rapidly switching the oste-
oclasts and osteoblast cells system into bone resorption mode,
leading to mobilisation of bone calcium reserve and decre-
asing kidney calcium excretion. At the same time, PTH acts
as an inducer kidney 1-hydroxylase which results in enhan-
ced synthesis of 1,25(OH)2D which in turn increases intesti-
nal calcium absorption, further activates the osteoclast/oste-
oblast system, feedback-downregulates its own production,
and stimulates an array of other catabolic genes involved in
bone turnover. A decrease of phosphate concentration in blo-
od serum stimulates 1-hydroxylase through the decreased
concentration of FGF23, leading to an increased concentra-
tion of the hormonal form of vitamin D in the circulation.
The increased 1,25(OH)2D stimulates intestinal phosphate
absorption and kidney phosphate retention, and bone resorp-
tion process to make up for the phosphate deficit in the cir-
culation. Therefore, vitamin D acts as a bone protection agent
only in a situation of proper supplementation of minerals and
vitamin D itself.
CORRELATION BETWEEN
DIFFERENT STATINS AND VITAMIN D LEVEL
Because of the convergence effect of statin therapy and vita-
min D supplementation in many ischaemic heart disease pre-
vention studies, scientists have been since the early 1990s
investigating the pleiotropic effect of statins via the vitamin D
metabolic pathway [11]. Surprisingly, observational studies
have shown different statin influences on vitamin D serum
levels depending on the type of statin administered.
In the STATIN-D study, there was a significant increase
in 25-hydroxyvitamin D from 11.8 to 35.2 ng/mL with ro-
suvastatin treatment (10 mg/day), whereas no significant
change in 25(OH)D was observed with fluvastatin treatment
(80 mg/day) [12]. In the JUPITER study, rosuvastatin at doses
of 20 mg/daily increased 25(OH)D in such a way that the
participants on average went from deficient to sufficient in
two months. The difference in CV risk between those defi-
cient and sufficient in vitamin D in observational studies
(described above) was similar to the risk reduction found in
JUPITER [12, 13]. On the other hand, the study of Rejnmark
et al. [14] found no effect of simvastatin (40 mg/day) on vita-
min D metabolites status. As far as atorvastatin is concerned,
Sathyapalan et al. [15] reported that its treatment (20 mg/day)




VITAMIN D AND STATINS
As we can see, the evidence for the importance of vitamin D
status in terms of the risk of CV events is strong and growing.
To translate these observations into molecular language, scien-
tists have tried to come up with a hypothesis that could explain
the similarity between the benefits of vitamin D and the be-
nefits of statin therapy.
Cholesterol and 25-hydroxyvitamin D have the same
precursor, namely 7-dehydrocholesterol, which is synthesi-
sed in a multiple-reaction pathway from acetyl-CoA with the
hydroxymethylglutaryl-CoA (HMG-CoA)-reductase activity
[16]. Levels of 7-dehydrocholesterol in the serum of healthy
individuals are around 0.3 mM and are directly correlated with
the activity of the HMG-CoA-reductase of the liver [17]. Sta-
tins, by reducing HMG-CoA-reductase activity, may decre-
ase the level of circulating 7-dehydrocholesterol. This view is
supported by cell culture experiments in which simvastatin
treatment increased the expression of genes involved in cho-
lesterol synthesis, including the D-7-sterol reductase [18].
Hence, it might be expected that there would be a reduction
of 25(OH)D synthesis with statins, although the opposite was
in fact shown in the described studies.
The hypothesis that the metabolic pathways of atorva-
statin and vitamin D somehow cross is supported by the stu-
dy of Schwartz [19]. There was reason to expect that incre-
asing vitamin D metabolites might enhance the clearance of
statin and its active metabolites and reduce the time-integra-
ted statin concentration. In the Schwartz study, vitamin D
supplementation indeed lowered atorvastatin and active
metabolite concentrations, yet unexpectedly had synergistic
effects on cholesterol concentrations.
A different influence on 25(OH)D level of each statin
has to be stressed when we try to come up with a theoretical
explanation. It has been proposed that differences in the bio-
availability and pattern of liver uptake between statins may
explain their different actions on vitamin D metabolism [11].
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CYP3A4 catabolises 25(OH)D in the liver. Statins are extensi-
vely metabolised by CYP3A4 and CYP3A5. Thus, Yavuz et al.
[11] have suggested that this CYP3A4 catabolic pathway may
be responsible for the increased 25(OH)D levels with the sta-
tin treatment which are known to cause drug interactions by
inhibiting the CYP enzyme system. Fluvastatin is a lipophylic
statin compound, whereas rosuvastatin is a hydrophilic statin
and has a relatively higher bioavailability. The hydrophilic
rosuvastatin has a slow rate of diffusion across cell membra-
nes, but is taken up rapidly by hepatocytes via active trans-
porter proteins. Such differences may translate into different
actions on vitamin D.
Finally, Grimes [20] has suggested that statins might
act as vitamin D analogues and compete with vitamin D
metabolites for its receptors. Although rosuvastatin does
not appear to significantly bind to the vitamin D receptor,
it does bind to the glucocorticoid receptor and the thyroid
beta-1 receptor, both of which strongly bind both 25(OH)D
and 1,25-dihydroxyvitamin D, which is also elevated by
rosuvastatin.
CONCLUSIONS
Evolving data indicates that vitamin D deficiency is playing an
important role in the genesis of coronary risk factors and ad-
verse CV events. It seems to predispose to hypertension, dia-
betes and metabolic syndrome, left ventricular hypertrophy,
congestive heart failure, and chronic vascular inflammation.
Overwhelming evidence supports the importance of vitamin
D status in the pathogenesis and progression of CV disease.
The entire thesis set out above has tried to explain the
observed interaction between statin and vitamin D serum le-
vel in CV disease prevention. Undoubtedly it is too complex,
and no simple explanation is sufficient to fully molecularly
describe the observations. In our opinion, the key to under-
standing the complexity of the interaction between statin and
vitamin D lies in the fact that vitamin D supplementation de-
creases statin metabolites concentration. Although the study
of Schwartz [19] involved a small number of patients, it focu-
sed the attention on the CYP3A4 enzymatic pathway. Large
randomised controlled trials are needed to firmly establish
the relevance of vitamin D status to vascular health and also
statins’ effects in reducing  CV risk.
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